

Polakit Teekakirikul

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/8333649/publications.pdf>

Version: 2024-02-01

22
papers

2,186
citations

687363

13
h-index

888059

17
g-index

22
all docs

22
docs citations

22
times ranked

4265
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic resiliency associated with dominant lethal TPM1 mutation causing atrial septal defect with high heritability. <i>Cell Reports Medicine</i> , 2022, 3, 100501.	6.5	0
2	Rare and Common Variants Uncover the Role of the Atria in Coarctation of the Aorta. <i>Genes</i> , 2022, 13, 636.	2.4	4
3	Common deletion variants causing protocadherin-1± deficiency contribute to the complex genetics of BAV and left-sided congenital heart disease. <i>Human Genetics and Genomics Advances</i> , 2021, 2, 100037.	1.7	7
4	Genetic Cardiomyopathies. , 2020, , 77-114.		1
5	Marked Up-Regulation of ACE2 in Hearts of Patients With Obstructive Hypertrophic Cardiomyopathy: Implications for SARS-CoV-2â€ Mediated COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1354-1368.	3.0	49
6	31â€...Fabry disease in east asia. , 2019, , .		0
7	33â€...Hypertrophic cardiomyopathy: pathogenesis, therapies and disease modulation. , 2019, , .		0
8	Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. <i>Biomolecules</i> , 2019, 9, 878.	4.0	78
9	Fabry Disease in Families With Hypertrophic Cardiomyopathy. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	17
10	Detection of Cell Proliferation Markers by Immunofluorescence Staining and Microscopy Imaging in Paraffinâ€ Embedded Tissue Sections. <i>Current Protocols in Molecular Biology</i> , 2016, 115, 14.25.1-14.25.14.	2.9	18
11	Nationwide Study on Hypertrophic Cardiomyopathy in Iceland. <i>Circulation</i> , 2014, 130, 1158-1167.	1.6	62
12	5â€RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. <i>Journal of Clinical Investigation</i> , 2014, 124, 1364-1370.	8.2	58
13	Inherited Cardiomyopathies. , 2013, , 1-38.		0
14	Inherited Cardiomyopathies. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 158-170.	2.8	172
15	Thoracic aortic disease in two patients with juvenile polyposis syndrome and <i>SMAD4</i> mutations. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 185-191.	1.2	51
16	Truncations of Titin Causing Dilated Cardiomyopathy. <i>New England Journal of Medicine</i> , 2012, 366, 619-628.	27.0	1,147
17	Hypertrophic cardiomyopathy: Translating cellular cross talk into therapeutics. <i>Journal of Cell Biology</i> , 2012, 199, 417-421.	5.2	40
18	Targeted Sequencing Using Affymetrix CustomSeq Arrays. <i>Current Protocols in Human Genetics</i> , 2011, 69, Unit7.18.	3.5	10

#	ARTICLE	IF	CITATIONS
19	Heterogeneous myocyte enhancer factor-2 (Mef2) activation in myocytes predicts focal scarring in hypertrophic cardiomyopathy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18097-18102.	7.1	47
20	Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf- β 2. Journal of Clinical Investigation, 2010, 120, 3520-3529.	8.2	372
21	Myofilament mechanical performance is enhanced by R403Q myosin in mouse myocardium independent of sex. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1939-H1947.	3.2	46
22	Streptococcus suis infection: overview of case reports in Thailand. Southeast Asian Journal of Tropical Medicine and Public Health, 2003, 34 Suppl 2, 178-83.	1.0	7